Roche licenses in a $2.3 billion BTK PROTAC

▤ Summary

Roche has signed an exclusive license and collaboration agreement with Nurix Therapeutics for Bexobrutideg (NX-5948), a BTK degrader candidate. The deal includes a $700 million upfront payment and total potential value of up to $2.3 billion if milestones are met. Roche and Nurix will share development costs and jointly commercialize the drug in the U.S., while Roche will handle commercialization outside the U.S. Bexobrutideg is an oral, brain-penetrant BTK PROTAC aimed at relapsed or refractory B-cell malignancies, with potential expansion into immune and neurological diseases.

▦ Linked Companies

Roche

$1B+